OncoMatch/Clinical Trials/NCT04921527
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Is NCT04921527 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including chiauranib and Paclitaxel for ovarian cancer.
Treatment: chiauranib · Paclitaxel — This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
platinum refractory or platinum resistant ovarian cancer
Cannot have received: VEGF/VEGFR inhibitor (Apatinib, Anlotinib, Fruquintinib, Bevacizumab)
Patients received vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR) inhibitor, like Apatinib, Anlotinib, Fruquintinib, Bevacizumab, etc.
Cannot have received: Aurora kinase inhibitor
Patients received ... Aurora kinase inhibitors.
Cannot have received: taxane (paclitaxel)
Exception: weekly schedule
Patients received weekly paclitaxel therapy.
Cannot have received: biological therapy
Biological therapy ... within 28 days prior to the first dose of study drug.
Cannot have received: immunotherapy
immunotherapy ... within 28 days prior to the first dose of study drug.
Cannot have received: hormonal therapy
hormonal therapy within 28 days prior to the first dose of study drug.
Cannot have received: investigational agent/instrument
Treatment with an investigational agent/instrument within 28 days prior to first dose of study drug.
Lab requirements
Blood counts
hemoglobin (Hb) ≥90g/L; absolute neutrophil count (ANC) ≥1.5×10^9/L; platelets ≥90×10^9/L
Kidney function
serum creatinine <1.5×ULN
Liver function
total bilirubin <1.5×ULN; ALT, AST ≤2.5×ULN (≤5×ULN if liver involved)
Laboratory criteria are as follows: Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×10^9/L ; platelets ≥90×10^9/L; Biochemistry test: serum creatinine(cr) <1.5×ULN; total bilirubin<1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≤2.5×ULN; (ALT,AST≤5×ULN if liver involved)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify